The human erythrocyte chemokine receptor has recently been shown to be identical to Invest. 1994.94:985-991.) 
Introduction
The chemokines are a family of pro-inflammatory molecules that have a variety of biological properties including leukocyte chemotaxis and activation (1) (2) (3) . The family is characterized by the presence of four conserved cysteine residues and has been classified into two separate groups dependent on whether the first two conserved cysteine residues are separated by an intervening amino acid (C-X-C) or whether they are adjacent (C-C) (1, 2) . The C-X-C class members include IL-8, melanoma growth stimulatory activity (MGSA),' and platelet factor 4 (PF4), while the C-C class members include regulated on activation, normal T expressed and secreted (RANTES); monocyte chemotactic protein-i (MCP-1); and macrophage inflammatory protein-1 (MIP-1) a and P.
The chemokines produce their biologic effects by interacting with specific receptors on the surface of their target cells (1) (2) (3) . Chemokine receptors can be grouped into two separate classes based on their ligand specificity. The first class belongs to the seven transmembrane spanning family of G-protein coupled receptors and binds either C-X-C or C-C chemokines (4) (5) (6) . The second class is exemplified by the erythrocyte chemokine receptor which has a broader ligand specificity and can accommodate both C-X-C and C-C chemokines (7, 8) .
Recently the erythrocyte chemokine receptor has been shown to be identical to the Duffy blood group antigen (9, 10). The Duffy blood group antigen was first identified serologically as the target of alloantibodies that can cause posttransfusion hemolytic reactions (11) . It was subsequently identified and characterized as a 35-43-kD membrane glycoprotein (12, 13) which is necessary for the invasion of human erythrocytes by the monkey malaria Plasmodium knowlesi (14) and the human malaria, Plasmodium vivax (15, 16) . Production of an anti-Duffy monoclonal antibody, anti-Fy6, (17) facilitated the purification and the subsequent cloning of the cDNA for the Duffy antigen receptor for chemokines (DARC) (18, 19) . The nucleotide sequence of the cDNA encoding the DARC predicts a primary structure with novel topologic features, that include an amino terminal extracellular domain, nine potential transmembrane spanning regions, and a cytoplasmic carboxyl-terminal tail (19) .
While transcripts encoding an isoform of the chemokine receptor can be detected in polyadenylated RNA from kidney and spleen (19) , the subpopulation of cells that express the receptor has not been localized and the functional relationship of the renal and erythroid isoforms has not been resolved. We performed experiments to identify the cell types in kidney that express this receptor, as well as studies to determine ligand binding characteristics, immunologic identity, and primary structure of the renal isoform.
Methods
Materials. '251-IL-8 and 251I-MGSA (specific activity 2,200 Cilmmol) were obtained from New England Nuclear (Boston, MA). Unlabeled IL-8 and MGSA were purified as previously described (8, 20 22 /ig per ml of IgG (17) .
Isolation of erythrocytes and production of erythrocyte ghosts. Human erythrocytes were isolated from whole blood using standard techniques (21) . Erythrocyte ghosts were prepared as described previously (8 (7, 8) . To demonstrate that the renal isoform of the DARC shares a spectrum of ligand binding that is similar to that of the erythrocyte DARC, we performed radioligand displacement experiments. The binding of '251-MGSA to human kidney membranes was completely displaced by excess unlabeled MGSA, IL-8, RANTES, and MCP-I (Fig. 3) . The (Fig. 4) . Coincubation with anti-Fy6 (at a final concentration of 3 nM) resulted in 88% inhibition of specific ligand binding but antibodies to the IL-8RA and IL-8RB (100 nM) had no effect on binding. (19) . A PCR product of 1.2 kbp, the size predicted from the mRNA transcript, was subcloned into the TA vector and sequenced. The nucleotide sequence of three clones was identical to that of the published sequence, except for two single base pair differences, which resulted in an alternative nucleotide (T instead of C) in the first position of codon 181 and (A instead of G) in the third position of codon number 182. Both sequences encode leucine residues in both positions. Computerized analysis of topologic features using the model of Eisenberg (25) (7) . B shows a diseased kidney section that has proliferation of small venules which stain prominently (arrows). Faint reactivity in a glomerulus (G) is localized to erythrocytes. Tubular epithelium (7) lacks significant reactivity.
presence of an amino terminal extracellular domain, seven transmembrane spanning regions, and a cytoplasmic carboxy-terminal tail. These features place the DARC in the superfamily of seven transmembrane domain G-protein coupled receptors (26) together with the other cloned chemokine receptors (3) .
Immunohistochemical localization of the DARC in kidney. The kidney is a structurally complex organ composed of blood vessels, glomeruli, and tubules with diverse functions. Immunohistochemistry was performed to identify the cell types that express the DARC. Staining of archival tissues with anti-Fy6 demonstrated that intense immunoreactivity was localized to the endothelial cells lining blood vessels. These structures were identified as venules because they were thin, irregular and lacked a significant mural structure (Fig. 5, A and B) . Staining appeared homogenous along small venules in a pattern most consistent with the staining of endothelial cells along this subset of the vasculature. Arteries, arterioles, capillaries, and veins were negative for staining with anti-Fy6 although they did show staining with anti-CD 34. Renal tubules in the cortex and medulla also lacked significant expression of the receptor, although a faint blush was-inconsistently evident in structures resembling proximal tubules.
Discussion
In this communication we present five separate lines of evidence to suggest that the DARC is expressed on endothelial cells of post capillary venules of human kidney. First, MGSA and antiFy6 bind to molecules of the same molecular mass (Figs. 1 and  2 ) which is similar, although slightly higher (possibly due to altered glycosylation), than the human erythrocyte DARC (7, 8) . Second, membranes prepared from human kidney display the same chemokine binding profile as that displayed by the human erythrocyte DARC (Figs. 3 and 4) . Third, the binding of the chemokine MGSA to kidney membranes is inhibited by anti-Fy6, but unaltered by monoclonal antibodies that block the binding of IL-8 and MGSA to IL-8RA and IL-8RB. Fourth, the nucleotide sequence of cDNA encoding the DARC isolated from renal tissue predicted a primary structure identical to that reported for the Duffy blood group antigen (19) . Finally, immu- (Fig. 5) .
Since the kidney is a highly perfused organ, it is a formal possibility that the biochemical data reflect, at least in part, Duffy antigen derived from erythrocytes. However, the renal and erythroid forms of DARC appear to be distinguishable by immunoblotting analysis (Fig. 1) . Furthermore, cells in the kidney that express DARC are clearly identified by immunohistochemistry (Fig. 5, A and B) . These cells, and not erythrocytes, are the source of the mRNA templates encoding DARC that were present in renal tissues. In addition antibodies to glycophorin A, which is expressed in erythrocyte membranes, crossreact as expected with erythrocyte membranes but not with renal membranes (data not shown). Thus, the constellation of findings supports the interpretation that the biochemical data is representative of DARC expressed by non-erythroid cells in the kidney.
Isoforms of other erythrocyte membrane proteins have been described in nonhematopoietic tissues (27) (28) (29) . These proteins may differ in primary structure from erythroid isoforms because of alternative splicing of pre-mRNA, as occurs for protein 4.1 (28, 29) , or tissue-specific transcriptional initiation as has been described for murine band 3 (30) . Also, tissue specific alternate promoters have been proposed for human band 3 (31) and glycophorin C (32, 33) , although these have not yet been identified. Proteins in nonhematopoietic tissue that are homologous to erythroid proteins but are encoded by separate genes have also been described (34) . It is clear that investigations into the structure and function of numerous erythrocyte membrane proteins are currently being extended to elucidate their structure and function in nonhematopoietic tissue.
In this report we present evidence that DARC is not specific to erythrocytes but is present along postcapillary venules of the kidney. Furthermore, preliminary data from our laboratories indicate that this protein is expressed along post-capillary venules throughout the body except for liver. The molecular basis of the tissue specific expression of DARC remains to be elucidated. It is clear from the present study that the amino acid sequence of DARC (deduced from cDNA) expressed in kidney is the same as that of DARC expressed on erythrocytes; it is possible, as has been suggested for glycophorin C, that tissue specificity is determined by alternate promoters.
The major finding of this study is the localization of DARC to endothelial cells that line postcapillary venules. Post-capillary venules are a dynamic interface that comprise the site for leukocyte transmigration from the vascular space into the tissue space during inflammation. This process, which is part of the inflammation cascade, is characterized by cytokine-mediated endothelial cell and leukocyte activation, selectin-mediated leukocyte rolling, integrin-mediated leukocyte adherence, and ultimately migration of the leukocyte out of the vascular space into the surrounding tissues along chemokine gradients (35) (36) (37) . Endo-thelial cells, activated by cytokines in vivo, produce IL-8 (20) , which may set up a chemotactic gradient favoring transendothelial diapedesis of leukocytes.
The localization of the DARC to endothelial cells of postcapillary venules, together with its ability to bind proinflammatory chemokines, suggests that it may play a major role in this inflammatory cascade. At least three distinct possibilities suggest themselves. First, the DARC of postcapillary venules could be involved in signal transduction that facilitates the interaction between immune cells and the endothelial cell. Second, the receptor could act as a docking protein to concentrate ligands at the cell surface for presentation to specific receptors on the appropriate immune cells. This mechanism has been suggested by Rot (38) , who demonstrated that radiolabeled IL-8, injected into rats, binds to post-capillary venules as determined by autoradiography of tissue sections. Interestingly such a role has been recently been described for MIP-1,. (39) , a member of the chemokine family that does not bind to the erythrocyte chemokine receptor. Alternatively, as suggested by Darbonne et al. (40) for erythrocytes the DARC might act as an intravascular sink, which could bind and inactivate circulating chemokines. This would presumably generate a chemokine gradient with higher concentrations of active chemokines found in the subendothelial matrix (41) , possibly bound to sulfated glycans (42) . Clearance of IL-8 from the plasma by binding to erythrocytes has been demonstrated in humans treated with IL-1 (43) . However, the significance of the erythrocyte chemokine receptor's role as a sink for chemokines must be interpreted in light of the fact that individuals who lack expression of this protein on their erythrocytes (44) , yet have no obvious abnormality in the regulation of inflammation. It is also possible that the DARC plays a role in angiogenesis that accompanies inflammation and/ or the growth of tumors as IL-8 has recently been implicated in angiogenesis and endothelial cell migration (45) .
In addition to their potential in furthering our understanding of events that modulate the inflammatory cascade, the findings reported here also underscore the concept of molecular heterogeneity of endothelial cells (46). Reactivity with Fy6 antibodies was exclusive to the endothelial cells of postcapillary venules, and was not a feature of endothelial cells of arteries, capillaries or large veins, including umbilical vein, which is unlike the global expression of CD34 and factor VIII molecules by endothelial cells (47) . The specificity of the microvascular location of DARC, as well as its binding of proinflammatory chemokines further supports a functional, rather than simply a structural role for this protein.
